Skip to main content

Table 2 Association of predictive factors with sustained virologic response among patients receiving anti-hepatitis C virus (HCV) treatment in chronically HCV/HIV co-infected patients, COHERE collaboration, 1998–2011, using logistic regression with forward selection of the variables included in the multivariate model

From: Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord

   Univariate p-value Multivariate p-value
   Odds ratio (95 % confidence interval)   Odds ratio (95 % confidence interval)  
Age at start HCV treatment (years) 16–34 1   1  
35–49 0.71 (0.51–0.99) 0.04 0.80 (0.52–1.23) 0.29
> = 50 0.68 (0.43–1.07) 0.10 0.58 (0.32–1.04) 0.06
Duration HCV treatment in weeks <24 1   1  
24–48 2.97 (2.23–3.95) <0.0001 2.85 (2.0–4.05) <0.0001
>48 3.72 (2.77–4.99) <0.0001 4.92 (3.43–7.08) <0.0001
Calendar year of starting HCV treatment <=2003 0.45 (0.32–0.64) <0.0001 0.41 (0.29–0.71) 0.0008
2003–2005 0.90 (0.69–1.18) 0.27 1.10 (0.78–1.59) 0.62
> = 2006 1   1  
BMI <25 1   1  
> = 25 0.69 (0.42–1.13) 0.14 1.01 (0.58–1.76) 0.97
unknown 1.85 (1.41–2.44) <0.0001 6.12 (3.99–9.38) <0.0001
Gender Male 1 0.57   -
Female 1.08 (0.84–1.38)    
HIV transmission route: MSM 1.80 (1.28–2.53) 0.0008   -
Male injection drug us (IDU) 1    
Female IDU 1.26 (0.91–1.74) 0.17   
Male heterosexual 1.03 (0.63–1.66) 0.92   
Female heterosexual 1.07 (0.68–1.68) 0.77   
Male other/unknown 1.18 (0.77–1.81) 0.45   
Female other/unknown 1.48 (0.80–2.75) 0.21   
Region of origin: Western 1    -
Other 1.07 (0.72–1.58) 0.75   
Unknown 1.67 (1.09–2.56) 0.02   
HIV RNA levels at baseline (copies/ml) <=400 1.00 (0.74–1.34) 0.99   -
>400 1    
Hepatitis B virus co-infection No 1    -
Yes 1.29 (0.74–2.25) 0.37   
unknown 0.94 (0.49–1.78) 0.58   
Nadir CD4 (cells/μl) <200 1   1  
> = 200 0.90 (0.72–1.14) 0.38 0.80 (0.57–1.12) 0.19
CD4 at baseline (cells/μl) 0–349 1   1  
350–499 0.93 (0.66–1.31) 0.68 0.69 (0.45–1.07) 0.09
> = 500 1.14 (0.84–1.54) 0.40 0.94 (0.62–1.42) 0.75
missing 0.69 (0.48–0.99) 0.04 0.10 (0.05–0.19) <0.0001
HCV RNA load at baseline <600,000 2.52 (1.86–3.43) <0.0001 2.06 (1.38–3.06) 0.0004
≥600,000 1   1  
missing 1.11 (0.85–1.44) 0.46 1.41 (0.90–2.20) 0.13
HCV genotypes 1 0.52 (0.32–0.87) 0.02 0.27 (0.14–0.51) <0.0001
1a 0.35 (0.25–0.50) <0.0001 0.25 (0.17–0.39) <0.0001
1b 0.35 (0.23–0.53) <0.0001 0.28 (0.16–0.47) <0.0001
2 & 3 1   1  
4 0.37 (0.24–0.60) <0.0001 0.32 (0.19–0.54) <0.0001
Other/unknown 0.74 (0.55–1.02) 0.69 0.70 (0.46–1.05) 0.023
APRIa score <0.5 1   1  
0.5–1.5 0.37 (0.28–0.50) <0.0001 0.41 (0.29–0.58) <0.0001
> = 1.5 0.26 (0.18–0.39) <0.0001 0.24 (0.15–0.39) <0.0001
unknown 0.92 (0.68–1.25) 0.61 0.61 (0.40–0.94) 0.023
Decline in haemoglobin (g/dl) No decline 1   1  
<=2.5 1.06 (0.69–1.62) 0.78 0.89 (0.52–1.51) 0.66
>2.5 1.93 (1.28–2.92) 0.002 1.36 (0.81–2.28) 0.24
missing 1.53 (1.08–2.19) 0.02 4.66 (2.81–7.72) <0.0001
cART use: PI 0.62 (0.41–0.92) 0.02 1.04 (0.62–1.75) 0.87
Boosted PI 0.59 (0.44–0.80) 0.0008 0.61 (0.41–0.91) 0.02
NNRT 1   1  
PI + NNRT 0.51 (0.27–0.97) 0.04 0.65 (0.29–1.44) 0.29
No PI and/or NNRT 0.54 (0.39–0.84) 0.006 0.78 (0.44–1.39) 0.39
Start after HCV treatment 0.86 (0.61–1.22) 0.40 NAb  
NRTI backbonea Start after HCV treatment 0.93 (0.65–1.33) 0.69 0.96 (0.57–1.61) 0.34
ABC + 3TC 0.79 (0.54–1.15) 0.22 0.74 (0.45–1.24) 0.25
AZT + 3TC 0.53 (0.34–0.82) 0.004 0.44 (0.24–0.80) 0.007
FTC + TDF 1   1  
TDF + 3TC 1.17 (0.76–1.78) 0.47 0.76 (0.44–1.32) 0.33
TDF + ABC 0.81 (0.42–1.55) 0.51 0.79 (0.35–1.78) 0.57
d4T + 3TC 0.41 (0.24–0.71) 0.001 0.46 (0.22–0.96) 0.04
other 0.50 (0.34–0.73) 0.0003 0.54 (0.32–0.91) 0.02
  1. aAPRI, aspartate amino transferase-to-platelet ratio; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase; NRTI, nucleoside analog reverse-transcriptaseinhibitor; ABC, abacavir, 3TC, lamivudine; AZT, zidovudine; FTC, emtricitabine; TDF, tenofovir; d4T, stavudine
  2. bOdds ratio could not be calculated due to collinearity with the NRTI backbone category ‘start after HCV treatment’